CombiGene AB
COJ0
Company Profile
Business description
CombiGene AB is a gene therapy explorer based in Sweden. The company is engaged in developing new methods for the treatment of neurological diseases and for epileptic patients who cannot be helped by available medical treatments at present. It develops gene therapies with the ambition to offer patients affected by severe life-changing diseases opportunities for a better life.
Contact
Agavagen 52A
LidingoSE-181 55
SWET: +46 704663163
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
9
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,158.70 | 9.80 | 0.12% |
| CAC 40 | 8,035.24 | 58.96 | -0.73% |
| DAX 40 | 22,827.56 | 171.59 | -0.75% |
| Dow JONES (US) | 41,710.11 | 243.21 | -0.58% |
| FTSE 100 | 8,644.75 | 57.24 | -0.66% |
| HKSE | 23,689.72 | 530.23 | -2.19% |
| NASDAQ | 17,581.01 | 110.61 | -0.63% |
| Nikkei 225 | 37,677.06 | 74.82 | -0.20% |
| NZX 50 Index | 12,113.54 | 58.82 | 0.49% |
| S&P 500 | 5,623.46 | 39.43 | -0.70% |
| S&P/ASX 200 | 7,931.20 | 12.30 | 0.16% |
| SSE Composite Index | 3,364.83 | 44.12 | -1.29% |